85 posters,  3 sessions,  26 topics,  73 authors 

ePostersLive® by SciGen® Technologies S.A. All rights reserved.

COS03
Initial outcome and toxicity of stereotactic ablative body radiotherapy (SABR) for early stage lung cancer in a single UK centre

Primary tabs

Poster Presenter
Authors
Affiliations

Rate

No votes yet

Statistics

264 reads
Initial outcome and toxicity of stereotactic ablative body radiotherapy (SABR) for early stage lung cancer in a single UK centre
Poster
Outcomes of treatment (including chemotherapy, chemo-RT and RT)
SABR is standard practice for peripheral early stage lung cancer patients’ who are medically inoperable. SABR was implemented from July 2014 at our centre. As part of quality reassurance, we analysed the survival outcomes and early toxicity of data in our patients.
Patients with T1-3N0M0 lung cancer referred to lung MDT who are inoperable are selected according to UK SABR Consortium guidelines. Retrospective analysis of electronic patient records and radiological imaging was performed. Survival analysis was calculated using Kaplan Meier estimate.
89 patients underwent SABR between July 2014 and November 2016. Baseline characteristics are showed in table 1. Median age was 75 (54-91) years. Median follow-up was 9 months defined from treatment start date to last clinical encounter or date of death. 

Mean overall survival was 23.7 months (95% CI 21.3- 26.1). Overall survival (OS) at 1 year is 80% and 2 years OS is estimated at 75%. Local control (LC) rate at 1 year was 96% and disease free rate was 84%. Analysis of failure rates showed 4% was in field local recurrence, 4% regional recurrence and 7% distant metastasis. These were similar to outcomes in Cardiff centre (L Sweeney) reporting 1-year OS at 82%, 2-year OS 67%; and LC at 1 year 97.8%.

Early toxicity data showed 57% (51/89) of patients did not report any grade of toxicity. 9% (8/89) reported grade 1 toxicity of shortness of breath (SOB), chest pain, cough and fatigue. 10% (9/89) reported grade 2 toxicity of SOB, chest wall pain; with 1 patient reporting pneumonitis and oesophagitis each. Grade 3 toxicity was only reported in 1 patient (1%) with rib fracture but patient remains alive.

Early follow-up data shows good outcomes of lung SABR at our centre with minimal toxicity and comparable to other UK centre.
Enter Poster ID (e.gGoNextPreviousCurrent